MYELOID LEUKEMIA AFTER CYTOTOXIC THERAPY AND OTHER HEMATOTOXINS

ISSN： 1087-2620

Source： Journal of Toxicology and Environmental Health, Vol.61, Iss.5-6, 2000-11, pp. : 381-386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing Therapy for Acute Myeloid Leukemia

By Kohrt Holbrook E. Coutre Steven E.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 1003-1016

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Developments of Differentiation Therapy of Acute Myeloid Leukemia

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 2, 2017-04 ,pp. : 86-105

Bentham Science Publishers

Access to resources Recommend Favorite

Development of personalized molecular therapy for acute myeloid leukemia

Current Pharmaceutical Biotechnology, Vol. 17, Iss. 1, 2016-01 ,pp. : 20-29

Bentham Science Publishers

Access to resources Recommend Favorite

Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy

By Frattini Mark G. Maslak Peter G.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 995-1002

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Proteomic Strategies for Individualizing Therapy of Acute MyeloidLeukemia (AML)

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 3, 2006-06 ,pp. : 159-170

Bentham Science Publishers

Access to resources Recommend Favorite